

University of Groningen

Biomarker signatures in pathophysiology and therapeutic interventions in inflammatory bowel diseases

Bourgonje, Arno R.

DOI:
[10.33612/diss.251123116](https://doi.org/10.33612/diss.251123116)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2023

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Bourgonje, A. R. (2023). *Biomarker signatures in pathophysiology and therapeutic interventions in inflammatory bowel diseases: a multimodal approach*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.251123116>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

**BIOMARKER SIGNATURES IN PATHOPHYSIOLOGY
AND THERAPEUTIC INTERVENTIONS
IN INFLAMMATORY BOWEL DISEASES**

A MULTIMODAL APPROACH

Arno R. Bourgonje

The publication of this thesis was financially supported by the University of Groningen, the Graduate School of Medical Sciences of the University Medical Centre Groningen, de Nederlandse Vereniging voor Gastro-enterologie (NVGE), Bourgonje Investments B.V., Cablon Medical B.V., Celltrion Healthcare, ChipSoft, Dr. Falk Pharma Benelux B.V., Ferring, Janssen Research & Development LLC, Nestlé, Olink, Sanquin Health Solutions Biologics Laboratory, Takeda, Teva Nederland and Tramedico.

Printed by Ipskamp Printing
Enschede, the Netherlands

Design & layout Bianca Pijl, www.pijlldesign.nl
Groningen, the Netherlands

© Copyright: 2023 A.R. Bourgonje, Groningen, the Netherlands

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior written permission of the author, or when appropriate, of the publishers of the publications included in this thesis.



rijksuniversiteit
groningen

BIOMARKER SIGNATURES IN PATHOPHYSIOLOGY AND THERAPEUTIC INTERVENTIONS IN INFLAMMATORY BOWEL DISEASES

A MULTIMODAL APPROACH

Proefschrift

ter verkrijging van de graad van doctor
aan de Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties

De openbare verdediging zal plaatsvinden op

woensdag 1 februari 2023 om 14.30 uur

door

Arno Rolf Bourgonje

geboren op 17 maart 1996
te Leeuwarden

Promotores

Prof. dr. G. Dijkstra

Prof. dr. K.N. Faber

Prof. dr. H. van Goor

Prof. dr. R.K. Weersma

Beoordelingscommissie

Prof. dr. B. Oldenburg

Prof. dr. P. Olinga

Prof. dr. C.J. van der Woude

Voor mijn ouders

Paranimfen

Dr. J.Z.H. von Martels

Drs. A.T. Otten

TABLE OF CONTENTS

Chapter 1	Introduction to the thesis	13
	PART I: IMMUNE-BASED BIOMARKERS IN IBD	37
Chapter 2	Antibody signatures in inflammatory bowel disease: current developments and future applications <i>Trends in Molecular Medicine 2022;28(8):693-705.</i>	39
Chapter 3	Genetic, environmental and intrinsic determinants of the human antibody epitope repertoire <i>Immunity 2022 (provisionally accepted)</i>	65
Chapter 4	In-depth characterization of the serum antibody epitope repertoire in inflammatory bowel disease using phage-display immunoprecipitation sequencing <i>Immunity 2022 (provisionally accepted)</i>	103
Chapter 5	Patients with inflammatory bowel disease show IgG immune responses towards specific intestinal bacterial genera <i>Frontiers in Immunology 2022;13:842911.</i>	153
Chapter 6	Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease <i>Submitted</i>	183
	Part II: INFLAMMATORY - AND FIBROSIS BIOMARKERS IN IBD	245
Chapter 7	Increased fecal calprotectin levels in Crohn's disease correlate with elevated serum Th1- and Th17-associated cytokines <i>PLoS One 2018;13(2):e0193202.</i>	247
Chapter 8	A combined set of four serum inflammatory biomarkers reliably predicts endoscopic disease activity in inflammatory bowel disease <i>Frontiers in Medicine 2019;6:251.</i>	263

Chapter 9	Assessing intestinal permeability in Crohn's disease patients using orally administered ⁵² Cr-EDTA <i>PLoS One 2019;14(2):e0211973.</i>	293
Chapter 10	Serological biomarkers of type I, III, and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn's disease <i>Alimentary Pharmacology and Therapeutics 2022;56(4):675-693.</i>	315
Chapter 11	The effect of phenotype and genotype on the plasma proteome in patients with inflammatory bowel disease <i>Journal of Crohn's and Colitis 2022;16(3):414-429.</i>	363
Chapter 12	Proteomic analyses do not reveal subclinical inflammation in fatigued patients with clinically quiescent inflammatory bowel disease <i>Scientific Reports 2022;12(1):14581.</i>	413
Chapter 13	Long-term dietary patterns are reflected in the plasma inflammatory proteome of patients with inflammatory bowel disease <i>Nutrients 2022;14(12):2522.</i>	453
	PART III: OXIDATIVE STRESS BIOMARKERS IN IBD	489
Chapter 14	Oxidative stress and redox-modulating therapeutics in inflammatory bowel disease <i>Trends in Molecular Medicine 2020;26(11):1034-1046.</i>	491
Chapter 15	Serum free thiols predict cardiovascular events and all-cause mortality in the general population: a prospective cohort study <i>BMC Medicine 2020;18(1):130.</i>	519
Chapter 16	Crohn's disease in clinical remission is marked by systemic oxidative stress <i>Frontiers in Physiology 2019;10:499.</i>	547
Chapter 17	Serum free thiols are superior to fecal calprotectin in reflecting endoscopic disease activity in inflammatory bowel disease <i>Antioxidants 2019;8(9):351.</i>	569
Chapter 18	HIF1 α -dependent induction of <i>TFRC</i> by a combination of intestinal inflammation and systemic iron deficiency in inflammatory bowel disease <i>Frontiers in Physiology 2022;13:889091.</i>	595

PART IV: EVALUATING THERAPEUTIC EFFECTS ON BIOMARKERS IN IBD

631

- Chapter 19** Inulin-grown *Faecalibacterium prausnitzii* cross-feeds fructose to the human intestinal epithelium 633
Gut Microbes 2021;13(1):1993582.
- Chapter 20** Vitamin C supplementation in healthy individuals leads to shifts of bacterial populations in the gut: a pilot study 667
Antioxidants 2021;10(8):1278.
- Chapter 21** The effect of riboflavin supplementation on the systemic redox status in healthy volunteers: a post-hoc analysis of the RIBOGUT trial 687
Free Radical Biology and Medicine 2022;190:169-178.
- Chapter 22** Riboflavin supplementation in patients with Crohn's disease (the RISE-UP study) 719
Journal of Crohn's and Colitis 2020;14(5):595-607.
- Chapter 23** The effect of induction therapy with infliximab or vedolizumab on hepcidin and iron status in patients with inflammatory bowel disease 757
Submitted
- Chapter 24** Serological biomarkers of intestinal collagen turnover identify early response to infliximab therapy in patients with Crohn's disease 795
Frontiers in Medicine 2022;9:933872.
- Chapter 25** Serological biomarkers of extracellular matrix turnover and neutrophil activity are associated with long-term use of vedolizumab in patients with Crohn's disease 827
International Journal of Molecular Sciences 2022;23(15):8137.
- Chapter 26** Mucosal eosinophil abundance in non-inflamed colonic tissue is associated with response to vedolizumab induction therapy in inflammatory bowel disease 855
Journal of Clinical Medicine 2022;11(14):4141.

	PART V: COVID-19 AND IBD	887
Chapter 27	Angiotensin-converting enzyme-2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19) <i>Journal of Pathology 2020;251(3):228-248.</i>	889
Chapter 28	Treatment of severe acute ulcerative colitis in SARS-CoV-2-infected patients: report of three cases and discussion of treatment options <i>Therapeutic Advances in Gastroenterology 2021;14:17562848211012595.</i>	929
Chapter 29	Mild coronavirus disease 2019 (COVID-19) is marked by systemic oxidative stress: a pilot study <i>Antioxidants 2021;10(12):2022.</i>	947
Chapter 30	Use of tumor necrosis factor- α antagonists is associated with attenuated IgG antibody response against SARS-CoV-2 in vaccinated patients with inflammatory bowel disease <i>Frontiers in Immunology 2022;13:920333.</i>	969
	DISCUSSION	995
Chapter 31	Discussion, conclusions and future perspectives	997
Appendices		1047
	English summary	1049
	Nederlandse samenvatting	1057
	Curriculum vitae	1067
	List of publications	1071
	Dankwoord Acknowledgements	1085

